Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | GCGR | P47871 | 4/20 | 0.47 |
| ▸ | RXRA | P19793 | 3/20 | 0.46 |
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2662314 | 0.88 | CA1 (0.51) | NR1H4GCGRMAPTSMN1; SMN2KIF11 | |
| SCHEMBL2653872 | 0.86 | GCGR (0.63) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL3276719 | 0.82 | GCGR (0.52) | GCGRADCY6ADCY3ADCY9ADCY5 | |
| SCHEMBL29157149 | 0.76 | FFAR1 (0.52) | GCGRMEN1KMT2AKIF11ADCY6 | |
| SCHEMBL2655296 | 0.76 | GCGR (0.76) | GCGR | |
| SCHEMBL1765530 | 0.76 | RXRA (0.49) | NR1H4GCGRRXRARXRBRXRG | |
| SCHEMBL27765959 | 0.75 | NR1H4 (0.59) | NR1H4EPHX2RXRARXRBRXRG | |
| SCHEMBL2053275 | 0.75 | SRD5A2 (0.77) | NR1H4EPHX2RXRARXRBRXRG | |
| SCHEMBL9951730 | 0.73 | GCGR (0.65) | GCGR | |
| SCHEMBL9950967 | 0.73 | GCG (0.53) | EPHX2GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951661-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2012-08-08 | — | — | EP | disclosed |
| US-7696248-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-12-04 | — | — | US | disclosed |
| EP-1951661-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007106181-A2 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300308-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | NR1H4 139/4885EPHX2 2409/4885GCGR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.